Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Malcolm Taub Insider Profile
4 Followers
Malcolm Taub, Director at Brainstorm Cell Therapeutics, holds 77.33K shares in Brainstorm Cell Therapeutics (Ticker: BCLI).
Malcolm Taub Brainstorm Cell Therapeutics (BCLI)Director
Brainstorm Cell Therapeutics (BCLI)
Director
Ranked #48,641 out of 98,743 Corporate Insiders
Profitable Transactions
1 out of 2 Profitable Transactions
Average Return
+1.00%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Malcolm Taub holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Dec 16, 2015 - Dec 16, 2016
Return:+3.20%
The most profitable trade made by Malcolm Taub
Malcolm Taub's Trading History
List of latest transactions for each holding click on a transaction to see Malcolm Taub's performance on stock
You May Also Like
Malcolm Taub insider profile FAQ
What is the percentage of profitable transactions made by Malcolm Taub?
The percentage of profitable transactions made by Malcolm Taub is 50%.
What is the average return per transaction made by Malcolm Taub?
The average return per transaction made by Malcolm Taub is 1.00%.
What stocks does Malcolm Taub hold?
Malcolm Taub holds: BCLI stocks.
What was Malcolm Taub’s latest transaction?
Malcolm Taub latest transaction was an Uninformative Buy of ―.
What was Malcolm Taub's most profitable transaction?
Malcolm Taub’s most profitable transaction was an Informative Sell of BCLI stock on December 16, 2015. The return on the trade was 3.20%.
What is Malcolm Taub's role in Brainstorm Cell Therapeutics?
Malcolm Taub's role in Brainstorm Cell Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.